NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models

Cephalalgia

Volumn 33, Issue 2, 2013, Pages 87-100

  Bhatt, Deepak K ^a   Gupta, Saurabh ^a   Jansen Olesen, Inger ^a   Andrews, John S ^b   Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NeurAxon Inc   (Canada)

Author keywords

CGRP; dura mater; migraine; trigeminal ganglion; trigeminal nucleus caudalis; triptans

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; METITEPINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NXN 188; NXN 413; POTASSIUM CHLORIDE; RESINIFERATOXIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SELECTIVITY; DURA MATER; ELECTROSTIMULATION; ENZYME IMMUNOASSAY; EXPERIMENTAL MODEL; MALE; MENINGEAL ARTERY; MIGRAINE; NONHUMAN; PROTEIN SECRETION; RAT; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION; VAS DEFERENS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MIGRAINE DISORDERS; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84871577949     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412466967     Document Type: Article

References (51)

1. Medve RA, Andrews JS. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura [abstract PC.23]. Presented at the European Headache and Migraine Trust International Congress 2008. London, UK, 4-7 September 2008. Cephalalgia. 2009 ; 29: 126-126
2. Villalon CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009 ; 124: 309-323
3. Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics. 2010 ; 7: 183-190
4. Messlinger K, Lennerz JK, Eberhardt M, et al. CGRP and NO in the trigeminal system: Mechanisms and role in headache generation. Headache. 2012 ; 52: 1411-1427
5. Thomsen LL, Kruuse C, Iversen HK, et al. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol. 1994 ; 1: 73-80 (Pubitemid 2141297)
6. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002 ; 22: 54-61 (Pubitemid 34626025)
7. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet. 1997 ; 349: 401-402 (Pubitemid 27077677)
8. Ashina M, Lassen LH, Bendtsen L, et al. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: A randomised crossover trial. Lancet. 1999 ; 353: 287-289 (Pubitemid 29088122)
9. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 ; 350: 1104-1110 (Pubitemid 38298990)
10. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 ; 372: 2115-2123
11. Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache. 2011 ; 51: 64-72
12. Akerman S, Williamson DJ, Kaube H, et al. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002 ; 137: 62-68 (Pubitemid 34983464)
13. Naik AK, Tandan SK, Kumar D, et al. Nitric oxide and its modulators in chronic constriction injury-induced neuropathic pain in rats. Eur J Pharmacol. 2006 ; 530: 59-69 (Pubitemid 43037125)
14. Yoon YW, Sung B, Chung JM. Nitric oxide mediates behavioral signs of neuropathic pain in an experimental rat model. Neuroreport. 1998 ; 9: 367-372 (Pubitemid 28109189)
15. Osborne MG, Coderre TJ. Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Br J Pharmacol. 1999 ; 126: 1840-1846 (Pubitemid 29213103)
16. Bonnefous C, Payne JE, Roppe J, et al. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J Med Chem. 2009 ; 52: 3047-3062
17. Symons KT, Nguyen PM, Massari ME, et al. Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. J Pharmacol Exp Ther. 2011 ; 336: 468-478
18. Buzzi MG, Carter WB, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology. 1991 ; 30: 1193-1200
19. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 ; 33: 48-56 (Pubitemid 23009909)
20. Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999 ; 19: 3423-3429 (Pubitemid 29203122)
21. Limmroth V, Katsarava Z, Liedert B, et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain. 2001 ; 92: 101-106 (Pubitemid 32367941)
22. Eltorp CT, Jansen-Olesen I, Hansen AJ. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia. 2000 ; 20: 838-844 (Pubitemid 32154566)
23. Amrutkar DV, Ploug KB, Hay-Schmidt A, et al. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 2012 ; 153: 830-838
24. Vaughan D, Speed J, Medve R, et al. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Clinical Therapeutics. 2010 ; 32: 146-160
25. Bhatt DK, Ploug KB, Ramachandran R, et al. Activation of PAR-2 elicits NO-dependent and CGRP-independent dilation of the dural artery. Headache. 2010 ; 50: 1017-1030
26. Gupta S, Amrutkar DV, Mataji A, et al. Evidence for CGRP re-uptake in rat dura mater encephali. Br J Pharmacol. 2010 ; 161: 1885-1898
27. Sheykhzade M, Gupta S, Sorensen T, et al. Characterization of capsaicin induced responses in mice vas deferens: Evidence of CGRP uptake. Eur J Pharmacol. 2011 ; 667: 375-382
28. Hua XY, Wong S, Jinno S, et al. Pharmacology of calcitonin gene related peptide release from sensory terminals in the rat trachea. Can J Physiol Pharmacol. 1995 ; 73: 999-1006
29. Williamson DJ, Hargreaves RJ, Hill RG, et al. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia. 1997 ; 17: 525-531 (Pubitemid 27248490)
30. Petersen KA, Birk S, Doods H, et al. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol. 2004 ; 143: 697-704 (Pubitemid 39611605)
31. Morikawa T, Matsuzawa Y, Makita K, et al. Antimigraine drug, zolmitriptan, inhibits high-voltage activated calcium currents in a population of acutely dissociated rat trigeminal sensory neurons. Mol Pain. 2006 ; 2: 10-10
32. Xiao Y, Richter JA, Hurley JH. Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol Pain. 2008 ; 4: 12-12
33. Yu XJ, Cutrer FM, Moskowitz MA, et al. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology. 1997 ; 36: 83-91 (Pubitemid 27115845)
34. Skingle M, Beattie DT, Scopes DI, et al. GR127935: A potent and selective 5-HT1D receptor antagonist. Behav Brain Res. 1996 ; 73: 157-161
35. Selkirk JV, Scott C, Ho M, et al. SB-224289-a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol. 1998 ; 125: 202-208 (Pubitemid 28418773)
36. Gaster LM, Blaney FE, Davies S, et al. The selective 5-HT1B receptor inverse agonist 1′-methyl-5-[[2′-methyl-4′-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem. 1998 ; 41: 1218-1235 (Pubitemid 28208177)
37. Dieterle A, Fischer MJ, Link AS, et al. Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia. 2011 ; 31: 31-42
38. Knyihar-Csillik E, Vecsei L. Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater. Neurosci Lett. 1999 ; 260: 97-100 (Pubitemid 29066874)
39. Jancso N, Jancso-Gabor A, Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother. 1967 ; 31: 138-151
40. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience. 1988 ; 24: 739-768
41. Szallasi A, Blumberg PM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience. 1989 ; 30: 515-520 (Pubitemid 19168499)
42. Gupta S, Lozano-Cuenca J, Villalón CM, et al. Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries. Naunyn Schmiedebergs Arch Pharmacol. 2007 ; 375: 29-38 (Pubitemid 46354558)
43. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998 ; 21: 531-543 (Pubitemid 28475505)
44. Loyd DR, Weiss G, Henry MA, et al. Serotonin increases the functional activity of capsaicin-sensitive rat trigeminal nociceptors via peripheral serotonin receptors. Pain. 2011 ; 152: 2267-2276
45. Gupta S, Bhatt DK, Boni LJ, et al. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia. 2010 ; 30: 27-36
46. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol. 2004 ; 142: 1354-1360 (Pubitemid 39178889)
47. Muñoz-Islas E, Lozano-Cuenca J, González-Hernández A, et al. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. Eur J Pharmacol. 2009 ; 615: 133-138
48. Sánchez-López A, Centurión D, Vázquez E, et al. Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: Pharmacological correlation with the 5-HT1B and 5-HT1D subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: 220-227 (Pubitemid 38270779)
49. González-Hernández A, Muñoz-Islas E, Lozano-Cuenca J, et al. Activation of 5-HT1B receptors inhibits the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol. 2010 ; 637: 131-137
50. González-Hernández A, Manrique-Maldonado G, Lozano-Cuenca J, et al. The 5-HT(1) receptors inhibiting the rat vasodepressor sensory CGRPergic outflow: Further involvement of 5-HT(1F), but not 5-HT(1A) or 5-HT(1D), subtypes. Eur J Pharmacol. 2011 ; 659: 233-243
51. Medve RA, Lategan TW. A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura [abstract 190]. Presented at the 2nd European Headache and Migraine Trust International Congress 2010. Nice, France, 28-31 October 2010. J Headache Pain. 2010 ; 11: 38-38